Detection of bladder cancer
AssigneeBoard of Regents, The University of Texas System
InventorsWoonbok Chung, Bogdan A. Czerniak, Jean-Pierre Issa
Life of this patent
Estimating the term…
Abstract
Provided are methods for detecting bladder cancer in a subject. In some aspects, methylation of one or more of MYO3A, CA10, NKX6-2, SOX11, DBC1, NPTX2, and/or A2BP1 in DNA sediment from a urine sample may be evaluated to detect the presence or absence of a bladder cancer in a human patient.
Claims34
A method of detecting the presence of, or an increased risk of, a bladder cancer in a subject, comprising detecting or measuring methylation in at least one of MYO3A, CA10, NKX6-2, SOX11, DBC1, NPTX2, and A2BP1 in a biological sample from the subject, wherein methylation in the at least one of MYO3A, CA10, NKX6-2, SOX11, DBC1, NPTX2, and A2BP1 indicates that the subject has, or has an increased risk of having, the bladder cancer.
A kit comprising a sealed container comprising primers or probes designed to detect methylation in at least two genes selected from the group consisting of MYO3A, CA10, NKX6-2, SOX11, DBC1, NPTX2, and A2BP1.
A biochip comprising an isolated nucleic acid comprising primers to detect methylation in at least two genes selected from the group consisting of MYO3A, CA10, NKX6-2, SOX11, DBC1, NPTX2, and A2BP1.
Dependencies are inferred from the claim text.